Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The 47-year-old DRDO scientist scientist Bharat Bhushan Kataria, who police say planted a bomb inside Rohini court to kill his neighbour, allegedly learnt how to make a bomb online, including on YouTube.
The arrested scientist allegedly ordered several devices from e-commerce websites and ammonium nitrate from a local shop. He spent around Rs 5,000.
Getting fined for not appearing before court; his wife being detected with cancer; having to pay Rs 50,000 rent; and the possibility of facing criminal charges — these are some of the key factors that, police believe, drove the DRDO scientist over the edge.
Police found that Kataria’s neighbour had filed a criminal case against him and during the hearings on November 1, the court fined him Rs 1,000 for “unnecessary adjournment”.
Police said that Kataria was not getting leave from his office to attend the court hearings.         
Kataria also faced a legal suit by his neighbour over installing a water tank. He had moved to live in an apartment on rent and had recently discovered that his wife had cancer. 

Rohini court blast: DRDO scientist learnt bomb making online; here's why he took extreme step

Captions:&nbsp;
47-year-old DRDO scientist planted a bomb inside Rohini&nbsp;Court to kill neighbour
Bharat Bhushan Kataria&nbsp;allegedly learned how to make bomb online, including YouTube
Scientist ordered devices from e-commerce websites to construct the bomb
Personal issues might be the triggering points to push the scientist to the edge: Police&nbsp;
Kataria's&nbsp;neighbour&nbsp;had filed&nbsp;a criminal case against him
Kataria&nbsp;faced a legal suit by his neighbor over installing a water tank.&nbsp;
&nbsp;

Rohini&nbsp;court blast:&nbsp;DRDO&nbsp;scientist learnt bomb making online; here's why he took extreme step

The 47-year-old DRDO scientist&nbsp;Bharat Bhushan Kataria, who police say planted a&nbsp;bomb inside Rohini court&nbsp;to kill his neighbor, allegedly learned how to make a bomb online, including on YouTube.
The arrested scientist allegedly ordered several devices from e-commerce websites and ammonium nitrate from a local shop. He spent around Rs 5,000.
Getting fined for not appearing before the court; his wife being detected with&nbsp;cancer; having to pay Rs 50,000 rent; and the possibility of facing criminal charges &mdash; these are some of the key factors that, police believe, drove the DRDO scientist over the edge.
Police found that&nbsp;Kataria&rsquo;s neighbor had filed a criminal case against him and during the hearings on November 1, the court fined him Rs 1,000 for &ldquo;unnecessary adjournment&rdquo;.
Police said that Kataria was not getting leave from his office to attend the court hearings.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kataria also faced a legal suit by his neighbour over installing a water tank. He had moved to live in an apartment on rent and had recently discovered that his wife had cancer.&nbsp;

DRDO successfully conducted the flight test of an indigenously developed anti-tank guided missile, providing a major boost to the Indian Army

DRDO successfully test-fired homegrown anti-tank guided missile

Boost for Indian Army:&nbsp;DRDO&nbsp;successfully test-fires anti-tank guided missile
Low weight anti-tank guided missile launched from a man-portable launcher
Man-Portable Anti-Tank Guided Missile is integrated with thermal sight
DRDO:&nbsp;missile hit the target and destroyed it with precision
&nbsp;

DRDO successfully conducted the flight test of an indigenously developed anti-tank guided missile, providing a major boost to the Indian Army

The Defence Research and Development Organisation (DRDO) successfully conducted the flight test of an indigenously developed anti-tank guided missile, providing a major boost to the Indian Army, the defence body said Wednesday.
The low weight, fire and forget, anti-tank guided missile was launched from a man-portable launcher integrated with a thermal sight, the DRDO&nbsp;said.
It also added that the missile hit the target, a dummy tank, in direct attack mode and destroyed it with precision.

India on Monday successfully test-fired its new generation nuclear-capable Agni Prime missile from a defence base off Odisha coast...

India successfully test-fires Agni Prime missile off Odisha coast

The DRDO, which developed the missile,&nbsp;said the nuclear-capable missile met all mission objectives with high level of accuracy.

India on Monday successfully test-fired its new generation nuclear-capable Agni Prime missile from a defence base off Odisha coast.
An official statement by DRDO said the surface-to-surface ballistic missile has a range of 1000 to 2000 km.
The sleek missile, which is an advanced variant in the Agni series, was test-fired from a mobile launcher off the Abdul Kalam Island in Odisha at 10.55 am.
Its trajectory was monitored by sophisticated tracking radars and telemetry along the coast line.
The DRDO, which developed the missile,&nbsp;said the nuclear-capable missile met all mission objectives with high level of accuracy.
&nbsp;

The DRDO, which developed the missile,&nbsp;said the nuclear-capable missile met all mission objectives with high level of accuracy.

India on Monday successfully test-fired its new generation nuclear-capable Agni Prime missile from a defence base off Odisha coast. An official statement by DRDO said the surface-to-surface ballistic missile has a range of 1000 to 2000 km.
The sleek missile, which is an advanced variant in the Agni series, was test-fired from a mobile launcher off the Abdul Kalam Island in Odisha at 10.55 am.
Its trajectory was monitored by sophisticated tracking radars and telemetry along the coast line.
The DRDO, which developed the missile,&nbsp;said the nuclear-capable missile met all mission objectives with high level of accuracy.

A new study claims that DRDO's anti-Covid drug 2-DG is effective against all Covid-19 variants.As per the study, 2-DG reduces the multiplication of SARS-CoV-2 and alleviates the cells from infection-induced cytopathic effect (CPE) and cell death. The study suggests that the drug can be used in the treatment regimen. 
Based on these preliminary in-vitro findings, the molecule is now being moved for clinical trials in Covid patients. The study, published on June 15, has not yet been peer-reviewed.
The drug, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy&rsquo;s Laboratories, received approval for emergency use in moderate to severe cases of Covid-19 in May.
Clinical trials of 2-DG found that it enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy&rsquo;s Laboratories has launched 2-DG in the form of sachets. The first batch of the oral drug was released on May 17.
Two weeks ago, DRDO issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

DRDO's anti-Covid drug 2-DG found effective against all variants, says new study

A new study claims that DRDO's anti-Covid drug 2-DG is effective against all Covid-19 variants.As per the study, 2-DG reduces the multiplication of SARS-CoV-2 and alleviates the cells from infection-induced cytopathic effect (CPE) and cell death. The study suggests that the drug can be used in the treatment regimen.
Based on these preliminary in-vitro findings, the molecule is now being moved for clinical trials in Covid patients. The study, published on June 15, has not yet been peer-reviewed.
The drug, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy&rsquo;s Laboratories, received approval for emergency use in moderate to severe cases of Covid-19 in May.
Clinical trials of 2-DG found that it enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy&rsquo;s Laboratories has launched 2-DG in the form of sachets. The first batch of the oral drug was released on May 17.
Two weeks ago, DRDO issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

DRDO's anti-Covid drug 2-DG found effective against all variants: Study New study says DRDO's anti-Covid drug 2-DG is effective against all variants Study: 2-DG reduces the multiplication of SARS-CoV-2, prevents cell death Study on DRDO's 2-DG drug clears it for use in the Covid treatment regimen Drug moved for clinical trials in Covid patients, but study not peer-viewed 2-DG got approval for emergency use in moderate to severe cases in May Clinical trials showed that drug helped in faster recovery of Covid patients Dr. Reddy&rsquo;s Laboratories launched sachets of oral drug 2-DG on May 17 DRDO has given directions on the usage of its 2-DG drug on patients Drug should be avoided for those with comorbidities, diabetes or cardiac issues ----

A new study claims that DRDO's anti-Covid drug 2-DG is effective against all Covid-19 variants.As per the study, 2-DG reduces the multiplication of SARS-CoV-2 and alleviates the cells from infection-induced cytopathic effect (CPE) and cell death. The study suggests that the drug can be used in the treatment regimen.
Based on these preliminary in-vitro findings, the molecule is now being moved for clinical trials in Covid patients. The study, published on June 15, has not yet been peer-reviewed.
The drug, developed by the Defence Research and Development Organisation (DRDO) and Dr Reddy&rsquo;s Laboratories, received approval for emergency use in moderate to severe cases of Covid-19 in May.
Clinical trials of 2-DG found that it enables faster recovery of hospitalised Covid-19 patients and reduces their supplemental oxygen dependence. Dr. Reddy&rsquo;s Laboratories has launched 2-DG in the form of sachets. The first batch of the oral drug was released on May 17.
Two weeks ago, DRDO issued directions on the usage of its 2-DG drug on Covid-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

Dr Reddy&rsquo;s has fixed the price of the Defence Research and Development Organisation's (DRDO) 2DG anti-Covid drug at ₹990 per sachet. However, the central and state government hospitals would be given the medicine at a discount.
The second batch of 10,000 sachets of 2DG drug would be issued on May 27 by Dr Reddy&rsquo;s Lab.Union Defence Minister Rajnath Singh&nbsp;along with Union Health Minister Dr Harsh Vardhan had launched the first batch of the anti-COVID drug on May 17.
Earlier this month, the Drugs Controller General of India (DGCI) approved the drug for emergency use as an adjunct therapy in moderate to severe Covid cases.

Price of DRDO’s anti-Covid drug fixed at ₹990 per sachet

Dr Reddy&rsquo;s has fixed the price of the Defence Research and Development Organisation's (DRDO) 2DG anti-Covid drug at ₹990 per sachet. However, the central and state government hospitals would be given the medicine at a discount.
The second batch of 10,000 sachets of 2DG drug would be issued on May 27 by Dr Reddy&rsquo;s Lab.Union Defence Minister Rajnath Singh&nbsp;along with Union Health Minister Dr Harsh Vardhan had launched the first batch of the anti-COVID drug on May 17.
Earlier this month, the Drugs Controller General of India (DGCI) approved the drug for emergency use as an adjunct therapy in moderate to severe Covid cases.

Drug major Dr Reddy's Laboratories is working on the development of new treatment options for Covid-19 patients which it aims to launch over the next few month, the pharma&rsquo;s Co-Chairman &amp; Managing Director G V Prasad has said. The top official also ensured uninterrupted supplies of its existing range of products for the infectious disease in the market. The drug firm over the past few weeks has ramped up supply of multiple medicines including Remdesivir to meet the surge in demand, he added.
The Hyderabad-based drug major has already launched Sputnik V vaccine while partnering various organisations, including the Defence Research and Development Organisation.
&nbsp;

Dr Reddy’s developing new treatment options for COVID, top official says

Dr Reddy's&nbsp;developing new treatment options to fight Covid-19
Dr Reddy's&nbsp;MD&nbsp;ensured uninterrupted supplies of existing jabs, drugs
Drug major launched of Sputnik V vaccine in the country
Dr Reddy's&nbsp;also partners with organisations including&nbsp;DRDO
&nbsp;

Drug major Dr Reddy's Laboratories is working on the development of new treatment options for Covid-19 patients which it aims to launch over the next few month, the pharma&rsquo;s Co-Chairman &amp; Managing Director G V Prasad has said. The top official also ensured uninterrupted supplies of its existing range of products for the infectious disease in the market. The drug firm over the past few weeks has ramped up supply of multiple medicines including Remdesivir to meet the surge in demand, he added.
The Hyderabad-based drug major has already launched Sputnik V vaccine while partnering with various organisations, including the Defence Research and Development Organisation.
&nbsp;

Defence Research and Development Organisation (DRDO), has developed an antibody detection-based kit &lsquo;DIPCOVAN&rsquo;.
The kit will be useful for understanding Covid-19 epidemiology and assessing an individual&rsquo;s previous SARS-CoV-2 exposure. developed in association with Delhi-based Vanguard Diagnostics Pvt Ltd, the kit will help in&nbsp; qualitative detection &nbsp;antibodies in human serum or plasma.
According to a statement by the DRDO, DIPCOVAN offers a significantly faster turn-around time as it requires just 75 minutes to conduct the test.
Approved by the ICMR in April 2021, the kit will be sold across India from June first week for Rs 75 each. The kit has a shelf life of 18 months.

'DIPCOVAN': DRDO develops Covid-19 antibody detection kit 

DRDO develops&nbsp;antibody-based Covid&nbsp;detection kit
DIPCOVAN&nbsp;will assess individual's&nbsp;SARS-CoV-2 exposure
DIPCOVAN&nbsp;is a home kit, gives result in 75 minutes
Test kit to be available from June at&nbsp;₹75, shelf life 18 months
ICMR&nbsp;approve DRDO's&nbsp;DIPCOVAN&nbsp;in April 2021
&nbsp;
&nbsp;&nbsp;

Aiding India's fight against Covid-19, Defence Research and Development Organisation (DRDO), has developed an antibody detection-based kit &lsquo;DIPCOVAN&rsquo;.
The kit will be useful for understanding Covid-19 epidemiology and assessing an individual&rsquo;s previous SARS-CoV-2 exposure. Developed in association with Delhi-based Vanguard Diagnostics Pvt Ltd, the kit will help in qualitative detection&nbsp; of antibodies in human serum or plasma.
According to a statement by the DRDO, DIPCOVAN offers a significantly faster turn-around time as it requires just 75 minutes to conduct the test.
Approved by the ICMR in April 2021, the kit will be sold across India from June first week for Rs 75 each. The kit has a shelf life of 18 months.

Union Defence Minister Rajnath Singh and Health Minister launched the drug by distributing around 10,000 doses to some hospitals in the national capital.

Coronavirus Medicine | DRDO 2DG Anti Covid-19 Oral drug launched by Rajnath Singh

An anti-coronavirus drug developed by DRDO&nbsp;was formally launched on Monday. The oral drug has been found to be effective&nbsp;in cutting short the hospital stays of Covid&nbsp;patients

Launching today: Oral anti-Covid drug developed by DRDO

An anti-coronavirus drug developed by Defence Research and Development Organisation (DRDO) was formally launched on Monday. Union Defence Minister Rajnath Singh&nbsp;and Health Minister launched the drug by distributing&nbsp;around 10,000 doses to some hospitals in the national capital. The drug, called 2-deoxy-D-glucose or 2-DG, has been developed by a DRDO lab in collaboration with the Hyderabad-based pharma giant, Dr Reddy's Laboratories. Country's top regulator, the Drugs Controller General of India (DCGI), has approved the medicine for emergency use.
The oral drug was found to be safe for Covid-19 patients in phase 2 trials, conducted between May and October last year. It was found to be effective in cutting short the hospital stays of Covid patients and reducing their supplemental oxygen dependence.

An anti-coronavirus drug developed by Defence Research and Development Organisation (DRDO) was formally launched on Monday. Union Defence Minister Rajnath Singh&nbsp;and Health Minister launched the drug by distributing&nbsp;around 10,000 doses to some hospitals in the national capital.
The drug, called 2-deoxy-D-glucose or 2-DG, has been developed by a DRDO lab in collaboration with the Hyderabad-based pharma giant, Dr Reddy's Laboratories. Country's top regulator, the Drugs Controller General of India (DCGI), has approved the medicine for emergency use.
The oral drug was found to be safe for <a href="https://www.editorji.com/covid-19" target="_blank">Covid-19</a> patients in phase 2 trials, conducted between May and October last year. It was found to be effective in cutting short the hospital stays of Covid patients and reducing their supplemental oxygen dependence.
Also Read | <a href="https://www.editorji.com/story/covaxin-effective-against-india-uk-coronavirus-strains-bharat-biotech-1621174493845" target="_blank">Covaxin effective against India, UK coronavirus strains: Bharat Biotech</a>

The first batch of 10,000 doses of 2DG medicine for treating Covid-19 patients would be launched early next week, Defence Research and Development Organisation officials informed on Friday.
The drug manufacturers are working on ramping up the production of the medicine for future use. &nbsp;Production of the 2-DG drug on a large-scale will start soon in Hyderabad and at other centres too.
The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Hyderabad-based Dr Reddy's Laboratories.

DRDO’s 2DG medicine for treating Covid patients to be launched early next week

10,000 doses of 2-DG drug to be launched early next week
Developed by DRDO's&nbsp;INMAS&nbsp;in collaboration with&nbsp;Dr Reddy's
2DG drug production on large-scale to start soon in Hyderabad

The first batch of 10,000 doses of 2DG medicine for treating Covid-19 patients would be launched early next week, Defence Research and Development Organisation officials informed on Friday.
The drug manufacturers are working on ramping up the production of the medicine for future use. &nbsp;Production of the 2-DG drug on a large-scale will start soon in Hyderabad and at other centres too.
The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Hyderabad-based Dr Reddy's Laboratories.

The government on Wednesday approved the procurement of 1.5 lakh units of 'Oxycare' system, developed by the Defence Research and Development Organisation (DRDO). ₹322 crore have been sanctioned from the PM-CARES Fund for the purchase to help in the treatment of Covid-19 patients.
Oxycare is an oxygen supply system based on SpO2 (oxygen saturation) level. The DRDO has already transferred the technology to multiple industries in India for large-scale production of the Oxycare system.
The defence ministry said 1 lakh manual and 50,000 automatic Oxycare systems are being procured.
"The Oxycare system delivers supplemental oxygen based on the SpO2 levels and prevents a person from sinking into a state of hypoxia which can be fatal," the ministry said in a statement.
Oxycare was developed by DRDO for soldiers posted at extreme high-altitude areas.
&nbsp;

Oxygen crisis: Govt to buy 1.5 lakh units of DRDO's 'Oxycare' system for Covid patients

The government on Wednesday approved the procurement of 1.5 lakh units of 'Oxycare' system, developed by DRDO,&nbsp;to help in the treatment of&nbsp;Covid-19 patients

Oxygen crisis: Govt to buy 1.5 lakh units of DRDO's 'Oxycare' system

The government on Wednesday approved the procurement of 1.5 lakh units of 'Oxycare' system, developed by the Defence Research and Development Organisation (DRDO). ₹322 crore have been sanctioned from the PM-CARES Fund for the purchase to help in the treatment of Covid-19 patients.
Oxycare is an oxygen supply system based on SpO2 (oxygen saturation) level. The DRDO has already transferred the technology to multiple industries in India for large-scale production of the Oxycare system.
The defence ministry said 1 lakh manual and 50,000 automatic Oxycare systems are being procured.
"The Oxycare system delivers supplemental oxygen based on the SpO2 levels and prevents a person from sinking into a state of hypoxia which can be fatal," the ministry said in a statement.
Oxycare was developed by DRDO for soldiers posted at extreme high-altitude areas.
&nbsp;

The Drugs Controller General of India (DCGI) has given permission for the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 cases, the Defence Research and Development Organisation on Saturday.
The drug has been developed by DRDO lab Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy&rsquo;s Laboratories. "Clinical trial have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence," DRDO said on Saturday.
"Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty," it added.An adjunct therapy refers to an alternative treatment that is used together with the primary treatment. Its purpose is to assist the primary treatment.

DRDO's anti-Covid drug gets emergency use approval

The Drugs Controller General of India has given permission for the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 cases

The Drugs Controller General of India has given permission for the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 cases, the Defence Research and Development Organisation on Saturday. The drug has been developed by DRDO lab Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy&rsquo;s Laboratories. "Clinical trial have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence," DRDO said on Saturday. "Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty," it added. An adjunct therapy refers to an alternative treatment that is used together with the primary treatment. Its purpose is to assist the primary treatment.

The Drugs Controller General of India (DCGI) has given permission for the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 cases, the Defence Research and Development Organisation said on Saturday.
The drug has been developed by DRDO lab Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy&rsquo;s Laboratories. "Clinical trial have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence," DRDO said on Saturday.
"Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty," it added. An adjunct therapy refers to an alternative treatment that is used together with the primary treatment. Its purpose is to assist the primary treatment.

Amid a depleting Oxygen supply, the Centre has roped in the Indian Air Force to airlift oxygen cylinders and essential medicines.
Reports said that IAF has airlifted doctors and nursing staff from Kochi, Mumbai, Vizag and Bengaluru for setting up of a Defence Research and Development Organisation Covid hospital at Delhi.
The force has also airlifted oxygen containers of DRDO from Bengaluru for Covid centres at Delhi.
On Tuesday, Defence Minister Rajnath Singh directed all the defence establishments to setting up of more Covid-19 hospitals, use emergency powers and to bring in retired personnel to tackle the crisis.

Delhi: IAF roped in to bring in oxygen cylinders, medicines for DRDO's Covid hospital 

Indian Air Forces to airlift oxygen cylinders&nbsp;
Report: Force&nbsp;lifted heathworkers&nbsp;to setup DRDO&nbsp;hospital in Delhi&nbsp;
IAF&nbsp;airlifted oxygen containers&nbsp;for Covid centres at Delhi
Defence Minister directed all forces to tackle the crisis

Amid a depleting Oxygen supply, the Centre has roped in the Indian Air Force to airlift oxygen cylinders and essential medicines.
Reports said that IAF has airlifted doctors and nursing staff from Kochi, Mumbai, Vizag and Bengaluru for setting up of a Defence Research and Development Organisation Covid hospital at Delhi.
The force has also airlifted oxygen containers of DRDO from Bengaluru for Covid centres at Delhi.
On Tuesday, Defence Minister Rajnath Singh directed all the defence establishments to setting up of more Covid-19 hospitals, use emergency powers and to bring in retired personnel to tackle the crisis.

Nag anti-tank missile tested, ready to be inducted in Army

India on Thursday successfully carried out the final trial of the DRDO-developed Nag anti-tank guided missile with a warhead. Nag&nbsp;will now be inducted in Indian Army

India on Thursday successfully carried out the final trial of the DRDO-developed Nag anti-tank guided missile with a warhead. The test was carried out at 6:45 am at the Pokhran field firing ranges in Rajasthan. News agency ANI shared a picture of the target hit by the Nag missile during the final trial. The shoulder launched four kilometre range missile with Imaging Infra red seeker will now be inducted in Indian Army. The Nag trial comes after the DRDO tested the helicopter launched Stand-off Anti-Tank Missile (SANT) with beyond 10 km range on October 19.

Military offset part of Rafale deal still pending: CAG

The CAG has said that French jet maker Dassault, which is supplying Rafale fighter jets to India, has not yet confirmed technology transfer to DRDO which was part of the contract

The CAG has said that French jet maker Dassault, which is supplying Rafale fighter jets to India, has not yet confirmed technology transfer to DRDO which was part of the contract, the Hindustan Times has reported.&nbsp;The Comptroller and Auditor General, in a detailed report tabled in Parliament, has doubted if the transfer of technology for a key engine would even take place. It has also pointed out that several offset contracts built into multiple defence deals have &ldquo;not yielded the desired results&rdquo;. The first batch of five Rafale jets were inducted into the IAF two weeks ago.

Congrats DRDO: PM hails successful test of hypersonic technology

Prime Minister Narendra Modi on Monday applauded DRDO for successfully test firing hypersonic technology demonstrator vehicle for the first time.&nbsp;

Prime Minister Narendra Modi on Monday applauded DRDO for successfully test firing hypersonic technology demonstrator vehicle for the first time. In a tweet, the PM said&nbsp;the scramjet engine developed by our scientists helped the flight achieve a speed 6 times the speed of sound. The Defence&nbsp;Research and Development&nbsp;Organisation&nbsp;successfully flight tested the Hypersonic Technology Demonstrator Vehicle from Dr APJ Abdul Kalam Launch Complex at Wheeler Island or HSTDV off the coast of Odisha on Monday.&nbsp;Defence&nbsp;minister Rajnath Singh, too, congratulated the DRDO.

Prime Minister Narendra Modi on Monday applauded DRDO for successfully test firing hypersonic technology demonstrator vehicle for the first time. In a tweet, the PM said&nbsp;the scramjet engine developed by our scientists helped the flight achieve a speed 6 times the speed of sound. The Defence&nbsp;Research and Development&nbsp;Organisation&nbsp;successfully flight tested the Hypersonic Technology Demonstrator Vehicle from Dr APJ Abdul Kalam Launch Complex at Wheeler Island or HSTDV off the coast of Odisha on Monday.&nbsp;Defence&nbsp;minister Rajnath Singh, too, congratulated the DRDO.&nbsp;

drdo

Categories